
Bridget Martell on taking Yale spinout 'to adulthood'; Cullinan Oncology CEO announces resignation as Bristol Myers hematology exec is welcomed aboard
Bridget Martell’s first clinical trial was an unorthodox one.
Then a resident in internal medicine at Yale, she was given an award to explore a career in clinical research — which was how she wound up leading a Phase I study for a therapeutic cocaine vaccine designed to help overcome addiction. She ended up overseeing the trial from Patient 1 to Patient 110 and, in the end, the early trial was positive.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters